title: [The study of anti-tumor effect of Tetrandrine combined with Nedaplatin on human liver cancer cell line 7402].
abstract: OBJECTIVE
  To study the anti-tumor effect of Tetrandrine (Tet) combined with Nedaplatin (Nap) on the human liver cancer cell line 7402, and explore its mechanism.
  
  
  METHODS
  Human liver cancer line 7402 was treated by Tet and Nap in various concentrations respectively or in combination in vitro,and then the cell growth was assayed by MTT method, periodic return changes were observed by aridine orange (AO)-/ethidiumbromide (EB) fluorescent staining, DNA gel eledtophoresis and flow cytometry, and the expression of apoptosis-related genes were analyzed by immunohistochemical staining method.
  
  
  RESULTS
  Compared with Tet or Nap individual drug groups, Tet combined with Nap obviously increased the inhibitatory rate and apoptosis rate of the human liver cancer cell line 7402. The cell cycle distribution was altered and ratio of S phase and G2/M phase cell increased following the treatment with Tet combined with Nap, with Bcl-2 gene expression down-regulated, and BAX gene expression up-regulated.
  
  
  CONCLUSIONS
  Tet combined with Nap can obviously increase apoptosis-inducing effect, and its mechanism may be regulating cell cycle and increasing apoptosis-inducing effect which is regulated by several genes.
authors.affiliation: Department of Oncology, Henan Province Tumor Hospital, Zhengzhou 450008, China.
authors.forename: Wen-Ying
authors.initials: WY
authors.lastname: Deng
authors.forename: Su-Xia
authors.initials: SX
authors.lastname: Luo
authors.forename: Meng-Qiang
authors.initials: MQ
authors.lastname: Zhou
authors.forename: Ning
authors.initials: N
authors.lastname: Li
authors.forename: Xiao-Bing
authors.initials: XB
authors.lastname: Chen
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Han
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D044182:Benzylisoquinolines / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004357:Drug Synergism; D005434:Flow Cytometry; D006801:Humans; D020128:Inhibitory Concentration 50; D008113:Liver Neoplasms / Q000473:pathology; D029583:Menispermaceae / Q000737:chemistry*; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D010946:Plants, Medicinal / Q000737:chemistry; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D051028:bcl-2-Associated X Protein / Q000096:biosynthesis
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D044182:Benzylisoquinolines; D009944:Organoplatinum Compounds; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein; C009438:tetrandrine; C053989:nedaplatin